Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators

Area of Science:

• Cardiology
• Pharmacology

Background:

• High cardiovascular risk necessitates low-density-lipoprotein cholesterol (LDL-C) reduction to <70 mg/dL.
• Statins are primary treatments, but myopathy limits their use.
• Statin-related myopathy incidence is estimated up to 10.5%, varying between short-term and long-term trials.

Purpose of the Study:

• To review the incidence, influencing factors, and management strategies for statin-related myopathy.
• To explore alternative approaches for LDL-C reduction and statin-induced myopathy prevention.
• To highlight the importance of awareness and prevention of statin-related myopathy and rhabdomyolysis.

Main Methods:

• Literature review of statin-related myopathy incidence and contributing factors.
• Analysis of alternative lipid-lowering strategies and potential myopathy mitigation.
• Discussion of the role of genetics, dosage, and coenzyme Q10 in statin myopathy.

Main Results:

• Statin-related myopathy incidence may reach 10.5%, influenced by genetics and dose.
• Ezetimibe allows for lower statin doses, and intermittent rosuvastatin is an alternative regimen.
• Coenzyme Q10 supplementation's efficacy in preventing myopathy is unproven, though statins interfere with its cellular role.

Conclusions:

• Managing statin-related myopathy is crucial for high cardiovascular risk patients.
• Strategies like using ezetimibe or adjusting statin dosage can mitigate myopathy risks.
• Awareness of statin-related myopathy, including the rare but severe rhabdomyolysis, is essential for patient safety.